Rosenblatt downgrades OneSpan to Neutral, sets $18 target
Rosenblatt Securities cut its rating on OneSpan to Neutral from Buy and set an $18 price target.
Related stories
Phathom Pharmaceuticals Reports Quarterly Results
Phathom Pharmaceuticals reported results for the quarter ended September 30. The supplied text contains no financial figures.
M impact | EQUITY | Oct 29, 2026, 06:19 PM UTC
Equitas Small Finance Bank CEO Resigns Over Daughter’s Business
PN Vasudevan resigned as managing director and CEO, citing a potential conflict-of-interest overhang related to his daughter promoting a non-bank entity. The bank’s shares fell 20%
M impact | EQUITY | Oct 29, 2026, 06:19 PM UTC
Life Time Group Holdings Reports Quarterly Results
M impact | EQUITY | Oct 29, 2026, 06:17 PM UTC
RPG Life Sciences Q2 Revenue Rises 16.5% to ₹211.6 Crore
The pharmaceutical firm reported Q2 FY27 revenue from operations of ₹211.6 crore, up 16.5% year on year. Profit was ₹28.22 crore, versus ₹30.58 crore in Q1 FY27 and ₹36.85 crore in
M impact | EQUITY | Oct 29, 2026, 06:16 PM UTC
KKR Real Estate Finance Trust Reports Quarterly Results
The company reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 06:15 PM UTC
Oracle Shares Fall Over 3% as Company Sets $20 Billion Financing Ceiling
Oracle said it is capping additional fundraising at $20 billion as investors scrutinize the cash demands of its AI expansion. Shares traded at $140.14 on October 29, down approxima
M impact | EQUITY | Oct 29, 2026, 06:06 PM UTC